183 related articles for article (PubMed ID: 29438706)
1. A novel role of the antitumor agent tricyclodecan-9-yl-xanthogenate as an open channel blocker of KCNQ1/KCNE1.
Wu M; Takemoto M; Luo H; Xu JJ; Lu MH; Kameyama M; Takumi T; Song WJ
Eur J Pharmacol; 2018 Apr; 824():99-107. PubMed ID: 29438706
[TBL] [Abstract][Full Text] [Related]
2. Engineering a peptide inhibitor towards the KCNQ1/KCNE1 potassium channel (IKs).
Hu Y; Chen J; Wang B; Yang W; Zhang C; Hu J; Xie Z; Cao Z; Li W; Wu Y; Chen Z
Peptides; 2015 Sep; 71():77-83. PubMed ID: 26188173
[TBL] [Abstract][Full Text] [Related]
3. Regulation of membrane KCNQ1/KCNE1 channel density by sphingomyelin synthase 1.
Wu M; Takemoto M; Taniguchi M; Takumi T; Okazaki T; Song WJ
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C15-23. PubMed ID: 27194473
[TBL] [Abstract][Full Text] [Related]
4. The residue I257 at S4-S5 linker in KCNQ1 determines KCNQ1/KCNE1 channel sensitivity to 1-alkanols.
Xie C; Liu HW; Pan N; Ding JP; Yao J
Acta Pharmacol Sin; 2016 Jan; 37(1):124-33. PubMed ID: 26725740
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C epsilon mediates the inhibition of angiotensin II on the slowly activating delayed-rectifier potassium current through channel phosphorylation.
Gou X; Wang W; Zou S; Qi Y; Xu Y
J Mol Cell Cardiol; 2018 Mar; 116():165-174. PubMed ID: 29452158
[TBL] [Abstract][Full Text] [Related]
6. BACE1 modulates gating of KCNQ1 (Kv7.1) and cardiac delayed rectifier KCNQ1/KCNE1 (IKs).
Agsten M; Hessler S; Lehnert S; Volk T; Rittger A; Hartmann S; Raab C; Kim DY; Groemer TW; Schwake M; Alzheimer C; Huth T
J Mol Cell Cardiol; 2015 Dec; 89(Pt B):335-48. PubMed ID: 26454161
[TBL] [Abstract][Full Text] [Related]
7. The
Wang Y; Eldstrom J; Fedida D
Mol Pharmacol; 2020 Feb; 97(2):132-144. PubMed ID: 31722973
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the heterotetrameric K+ channel KCNQ1/KCNE1 by the AMP-activated protein kinase.
Alesutan I; Föller M; Sopjani M; Dërmaku-Sopjani M; Zelenak C; Fröhlich H; Velic A; Fraser S; Kemp BE; Seebohm G; Völkl H; Lang F
Mol Membr Biol; 2011 Feb; 28(2):79-89. PubMed ID: 21231794
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rg3 activates human KCNQ1 K+ channel currents through interacting with the K318 and V319 residues: a role of KCNE1 subunit.
Choi SH; Shin TJ; Lee BH; Chu DH; Choe H; Pyo MK; Hwang SH; Kim BR; Lee SM; Lee JH; Kim DH; Kim HC; Rhim HW; Nah SY
Eur J Pharmacol; 2010 Jul; 637(1-3):138-47. PubMed ID: 20399767
[TBL] [Abstract][Full Text] [Related]
10. Gating and flickery block differentially affected by rubidium in homomeric KCNQ1 and heteromeric KCNQ1/KCNE1 potassium channels.
Pusch M; Bertorello L; Conti F
Biophys J; 2000 Jan; 78(1):211-26. PubMed ID: 10620287
[TBL] [Abstract][Full Text] [Related]
11. Tricyclodecan-9-yl-xanthogenate (D609) mechanism of actions: a mini-review of literature.
Adibhatla RM; Hatcher JF; Gusain A
Neurochem Res; 2012 Apr; 37(4):671-9. PubMed ID: 22101393
[TBL] [Abstract][Full Text] [Related]
12. Modulation of functional properties of KCNQ1 channel by association of KCNE1 and KCNE2.
Toyoda F; Ueyama H; Ding WG; Matsuura H
Biochem Biophys Res Commun; 2006 Jun; 344(3):814-20. PubMed ID: 16631607
[TBL] [Abstract][Full Text] [Related]
13. Tight coupling of rubidium conductance and inactivation in human KCNQ1 potassium channels.
Seebohm G; Sanguinetti MC; Pusch M
J Physiol; 2003 Oct; 552(Pt 2):369-78. PubMed ID: 14561821
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of DNA synthesis in untransformed cells by the antiviral and antitumoral compound tricyclodecan-9-yl-xanthogenate (D609).
Kiss Z; Crilly KS; Chung T
Biochem Pharmacol; 1998 Mar; 55(6):915-8. PubMed ID: 9586966
[TBL] [Abstract][Full Text] [Related]
15. Dynamic partnership between KCNQ1 and KCNE1 and influence on cardiac IKs current amplitude by KCNE2.
Jiang M; Xu X; Wang Y; Toyoda F; Liu XS; Zhang M; Robinson RB; Tseng GN
J Biol Chem; 2009 Jun; 284(24):16452-16462. PubMed ID: 19372218
[TBL] [Abstract][Full Text] [Related]
16. KCNE2 is colocalized with KCNQ1 and KCNE1 in cardiac myocytes and may function as a negative modulator of I(Ks) current amplitude in the heart.
Wu DM; Jiang M; Zhang M; Liu XS; Korolkova YV; Tseng GN
Heart Rhythm; 2006 Dec; 3(12):1469-80. PubMed ID: 17161791
[TBL] [Abstract][Full Text] [Related]
17. Insulin treatment augments KCNQ1/KCNE1 currents but not KCNQ1 currents, which is associated with an increase in KCNE1 expression.
Wu M; Obara Y; Ohshima S; Nagasawa Y; Ishii K
Biochem Biophys Res Commun; 2017 Nov; 493(1):409-415. PubMed ID: 28882596
[TBL] [Abstract][Full Text] [Related]
18. KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting.
Wrobel E; Rothenberg I; Krisp C; Hundt F; Fraenzel B; Eckey K; Linders JT; Gallacher DJ; Towart R; Pott L; Pusch M; Yang T; Roden DM; Kurata HT; Schulze-Bahr E; Strutz-Seebohm N; Wolters D; Seebohm G
Nat Commun; 2016 Oct; 7():12795. PubMed ID: 27731317
[TBL] [Abstract][Full Text] [Related]
19. Rb+ efflux through functional activation of cardiac KCNQ1/minK channels by the benzodiazepine R-L3 (L-364,373).
Jow F; Tseng E; Maddox T; Shen R; Kowal D; Dunlop J; Mekonnen B; Wang K
Assay Drug Dev Technol; 2006 Aug; 4(4):443-50. PubMed ID: 16945016
[TBL] [Abstract][Full Text] [Related]
20. KCNE1 and KCNE3 modulate KCNQ1 channels by affecting different gating transitions.
Barro-Soria R; Ramentol R; Liin SI; Perez ME; Kass RS; Larsson HP
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7367-E7376. PubMed ID: 28808020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
